<DOC>
	<DOCNO>NCT02601586</DOCNO>
	<brief_summary>This study conduct three parallel group receive oxycodone , levodopa placebo , administer add-on therapy , addition usual antiparkinsonian treatment . As study focus chronic central neuropathic pain cause PD , effect study treatment evaluate 10-week treatment period</brief_summary>
	<brief_title>Effects PR Oxycodone Levodopa , v Placebo , Central Neuropathic Pain Parkinson 's Disease</brief_title>
	<detailed_description>The treatment period ( 11 week ) divide three period : 1 . A titration phase two week , dose treatment gradually increase three step : Level 1 ( D1 D5 ) : - Oxycodone : 10 mg PR/day bid ( 5 mg PR/5 mg PR ) - Levodopa : 100 mg/day bid ( 50 mg/50 mg ) Level 2 ( D6 D10 ) : - Oxycodone : 20 mg PR/day tid ( 10 mg/0 mg/10 mg ) - Levodopa : 150 mg/day tid ( 50 mg/50 mg/50 mg ) Level 3 ( D11to D15 ) : - Oxycodone : 40 mg PR/day tid ( 20 mg/0 mg/20 mg ) - Levodopa : 200 mg/day tid ( 100 mg/50 mg/50 mg ) 2 . A fixed dose period : level 3 dose maintain 8 week ( D16 D71 ) . The study treatment administer add-on therapy , usual antiparkinsonian treatment . If patient side effect level 3 dose , return level 2 dose authorize . 3 . A withdrawal period : The dose study treatment gradually reduce , eight-day period : For patient treat level 3 dose 8 week : decrease level 2 dose first 3 day ( D72 D74 ) ; decrease level 1 dose next 3 day ( D75 D77 ) . The treatment stop completely D78 . The last visit take place D79 , 2 day end treatment . For patient treat level 2 dose : decrease level 1 dose first 3 day ( D72 D74 ) , stop treatment D75 . The last visit take place D79 , 5 day end treatment .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Patients Parkinson 's disease accord UKPDSBB criterion Patients suffer chronic pain ( last 3 month ) Patients suffer central neuropathic pain cause PD , Patients PDrelated central neuropathic pain intensity least 3 point VAS ( average intensity last month ) , Patients type pain ( neuropathic nociceptive ) include neuropathic pain predominates Patients treat stable regimen dopaminergic drug ( levodopa and/or dopamine agonist ) least 4 week study dan throughout study Patients stable step 1 analgesic ( NSAIDS , acetaminophen ) coanalgesic ( antidepressant , antiepileptic ) treatment least 4 week study throughout study Patients suffer another parkinsonian syndrome De Novo patient ( patient never treat dopaminergic drug ) Patients intercurrent acute pain Patients suffer chronic disease cause pain ( rheumatoid arthritis , ankylose spondylitis , diabetic neuropathy , cancer etc . ) Patients treated neuroleptic Patients treat deep brain stimulation Patients clinically detectable behavioural disorder addiction Patients disable dyskinesias Patients painful restless legs syndrome Patients cognitive impairment ( MMS &lt; 25 ) unable complete various scale use study Hypersensitivity oxycodone , levodopa , benserazide combination drug Patients treat opioid drug ( step 2 3 ) Patients treat nonselective monoamine oxidase inhibitor ( MAOI ) Patients severe hepatocellular insufficiency Patients uncontrolled cardiovascular pulmonary disease Persistent constipation already result subocclusive state Patients treat antiemetic neuroleptic Patients angleclosure glaucoma Exclusion criterion relate MRI : Patients claustrophobia Patients hear aid , cardiac prosthesis , pacemaker , surgical clip Patients refuse informed abnormality detect MRI</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>